X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Breaks Below 50-Day Moving Average – Should You Sell?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report)’s share price crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.15 and traded as low as $2.98. X4 Pharmaceuticals shares last traded at $3.12, with a volume of 501,341 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, X4 Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Get Our Latest Analysis on XFOR

X4 Pharmaceuticals Stock Down 1.6%

The company has a current ratio of 13.22, a quick ratio of 12.86 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $309.35 million, a PE ratio of -4.66 and a beta of 0.47. The firm has a 50-day moving average of $3.15 and a two-hundred day moving average of $3.77.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. X4 Pharmaceuticals had a negative return on equity of 49.62% and a negative net margin of 474.74%. The firm had revenue of $2.88 million for the quarter, compared to analysts’ expectations of $2.78 million. On average, equities research analysts forecast that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Insider Buying and Selling

In other news, CFO David Kirske sold 11,767 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer directly owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.13% of the stock is owned by corporate insiders.

Institutional Trading of X4 Pharmaceuticals

A number of institutional investors have recently modified their holdings of XFOR. Perceptive Advisors LLC raised its holdings in shares of X4 Pharmaceuticals by 6.7% during the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares during the period. Russell Investments Group Ltd. lifted its position in X4 Pharmaceuticals by 2,871.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock worth $618,000 after acquiring an additional 206,080 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth approximately $917,000. Bank of America Corp DE lifted its position in X4 Pharmaceuticals by 321.3% during the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after acquiring an additional 114,915 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth approximately $313,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body. Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections. X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia.

Read More

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.